The early diagnosis of Alzheimer's disease (AD) has become important to the reversal and treatment of neurodegeneration which may be relevant to premature brain aging associated with chronic disease progression. The diagnosis of AD by various plasma biomarkers with clinical proteomics may now require the involvement of lipidomics and genomics to provide interpretation of proteomic results from various laboratories around the world. The high fat, high fibre and high carbohydrate diets may influence and determine the variability of the various plasma biomarkers with relevance to the early diagnosis of AD. The measurements of AD blood biomarkers may need to be assessed in both the fasting and feeding states to allow early, accurate and reproducible diagnosis of AD.

RELEVANT REFERENCES:

1. Huber H, Ashton NJ, Schieren A, Montoliu-Gaya L, Molfetta GD, Brum WS, Lantero-Rodriguez J, Grötschel L, Stoffel-Wagner B, Coenen M, Weinhold L, Schmid M, Blennow K, Stehle P, Zetterberg H, Simon MC. Levels of Alzheimer's disease blood biomarkers are altered after food intake-A pilot intervention study in healthy adults. Alzheimers Dement. 2023 Dec;19(12):5531-5540.

2. Zhang Y, Bi K, Zhou L, Wang J, Huang L, Sun Y, Peng G, Wu W. Advances in Blood Biomarkers for Alzheimer's Disease: Ultra-Sensitive Detection Technologies and Impact on Clinical Diagnosis. Degener Neurol Neuromuscul Dis. 2024 Jul 30;14:85-102.

3. The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer's Disease. Proteomes. 2016 Mar 31;4(2):14.

4. Evaluation of diagnostic tests in human health and disease. J Clin Path Lab Med. 2018;2(1):13-15.

More Ian J Martins's questions See All
Similar questions and discussions